Mindray Completes Subsidiary Integration in Wuhan with Registered Capital Surging Nearly Sevenfold

In December 2025, Mindray integrated its business entities in the Wuhan area. The company previously fully owned by Mindray, "Wuhan Mindray Bio-Medical Technology Co., Ltd."(hereinafter referred to as "Wuhan Mindray Bio-Medical")Has been "Wuhan Mindray Scientific Co.,Ltd."(hereinafter referred to as "Wuhan Mindray Scientific Co.,Ltd.")Absorption merger.

According to the information from the Tianyancha app,On December 8, 2025, the registered capital of Wuhan Mindray Scientific Co., Ltd. increased significantly from 300 million yuan to 2.3 billion yuan, marking an increase of approximately 667%.This RMB 2 billion capital increase happens to be the same as the original registered capital of Wuhan Biomedical.At the same time, Wuhan Mindray Scientific's shareholders added the listed company Mindray, and the legal representative changed from Shi Peng to Han Le.(Han Leyi, the original legal representative of Wuhan Mindray Bio-Medical, the party being merged)。

As the other end of the merger process, Wuhan Mindray Bio-Medical Electronics Co., Ltd. underwent deregistration filing on December 3, 2025, with the reason for deregistration explicitly recorded as "due to merger or division." The company was established in December 2019, with a registered capital of 2 billion yuan, and was previously wholly owned by Mindray.

After the merger,The business scope of Wuhan Mindray Scientific Co., Ltd. covers the research, development, production, and sales of Class I, II, and III medical devices.

This integration aims to optimize the management structure and concentrate resources on advancing the development and construction of Mindray's high-end medical equipment R&D and manufacturing base in Wuhan (also known as the "Global Second Headquarters").